Emgality vs Leqembi
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Emgality | US Leqembi | |
|---|---|---|
| Generic name | galcanezumab | lecanemab |
| Drug class | CGRP Antagonist (Biologic) | Anti-Amyloid Monoclonal Antibody |
| Treats | Migraine prevention, cluster headache | Early Alzheimer's disease |
| Category | Neurology | Neurology |
| Manufacturer | Eli Lilly | Eisai |
| Year approved | 2018 | 2023 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $110M | — |
| Common side effects | Injection site reactions, Constipation, Itching, Allergic reactions | Brain swelling (ARIA), Brain bleeding (ARIA), Infusion reactions, Headache |
Frequently asked questions
Is Emgality or Leqembi better?
Neither is universally "better." Emgality (galcanezumab) and Leqembi (lecanemab) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Emgality and Leqembi?
Emgality is a CGRP Antagonist (Biologic) made by Eli Lilly, while Leqembi is a Anti-Amyloid Monoclonal Antibody made by Eisai. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Emgality has the larger estimated TV advertising budget of the two.